Skyhawk Shares A Closer Look at SKY-0515 Data, Plus A Peek At Expanding US Trial Access
⏱️ 6 min read | New 12-month data from Skyhawk’s SKY-0515 is in and all four measures that make up the cUHDRS are at or above baseline, beating expected natural decline. Plus, a first look at expanding US trial sites. Read more
June 2026: This Month in Huntington’s Disease Research
⏱️ 10 min read | From the clinic, we heard from uniQure about their recent FDA meeting, a stem cell trial dosed its first participant, and Skyhawk shared data on SKY-0515. In the lab, the science of slowing HD at the DNA level keeps building. Read more
Precision Pruning with PROTACs: Selective Targeting of Toxic Huntingtin
⏱️6 min read | PROTACs act like a precision pruning tool, trimming away toxic huntingtin protein while leaving the healthy form intact. In cells and HD mice, this targeted clean-up improved health and slowed disease features. Read more
Your DNA Shouldn’t Cost You Your Insurance: What HD Families Need to Know
⏱️13 min read | Australia just made history by banning life insurers from using genetic testing against you. But for HD families in other countries, the laws meant to protect haven’t kept pace with the science. Let’s break down what you need to know. Read more
The Other Shoe Drops: uniQure Shares Plans To Submit Licensing Application With The FDA for AMT-130
⏱️ 9 min read | After a turbulent past year, uniQure have shared encouraging news that the FDA has agreed their Phase I/II study data can serve as the basis for an application that could lead to the approval of AMT-130 in the US. Read more
First participant dosed in pioneering neural stem cell trial for Huntington’s disease
A new clinical trial for HD is underway. The first participant has been dosed in REGEN4HD, a study testing whether transplanting neural stem cells is safe as a potential treatment for HD. Read more
EN 
ES 
IT 
DE 
FR